Camcevi Kit is a drug owned by Accord Biopharma Inc. It is protected by 4 US drug patents filed from 2021 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 01, 2039. Details of Camcevi Kit's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11717555 | Pharmaceutical compositions having a selected release duration |
Jan, 2039
(14 years from now) | Active |
| US10646572 | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(2 years from now) | Active |
| US9744207 | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(2 years from now) | Active |
| US9572857 | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(2 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Camcevi Kit's patents.
Latest Legal Activities on Camcevi Kit's Patents
Given below is the list of recent legal activities going on the following patents of Camcevi Kit.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9572857 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US10646572 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9744207 |
| transaction for FDA Determination of Regulatory Review Period | 07 Feb, 2024 | US10646572 |
| transaction for FDA Determination of Regulatory Review Period | 07 Feb, 2024 | US9744207 |
| transaction for FDA Determination of Regulatory Review Period | 07 Feb, 2024 | US9572857 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Oct, 2023 | US10646572 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 19 Oct, 2023 | US10646572 |
| Patent Issue Date Used in PTA Calculation Critical | 08 Aug, 2023 | US11717555 |
| Electronic Review Critical | 08 Aug, 2023 | US11717555 |
FDA has granted several exclusivities to Camcevi Kit. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Camcevi Kit, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Camcevi Kit.
Exclusivity Information
Camcevi Kit holds 1 exclusivities. All of its exclusivities have expired in 2024. Details of Camcevi Kit's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 25, 2024 |
US patents provide insights into the exclusivity only within the United States, but Camcevi Kit is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Camcevi Kit's family patents as well as insights into ongoing legal events on those patents.
Camcevi Kit's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Camcevi Kit's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 01, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Camcevi Kit Generics:
There are no approved generic versions for Camcevi Kit as of now.
About Camcevi Kit
Camcevi Kit is a drug owned by Accord Biopharma Inc. Camcevi Kit uses Leuprolide Mesylate as an active ingredient. Camcevi Kit was launched by Accord in 2021.
Approval Date:
Camcevi Kit was approved by FDA for market use on 25 May, 2021.
Active Ingredient:
Camcevi Kit uses Leuprolide Mesylate as the active ingredient. Check out other Drugs and Companies using Leuprolide Mesylate ingredient
Dosage:
Camcevi Kit is available in emulsion form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 42MG BASE | EMULSION | Prescription | SUBCUTANEOUS |